Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma

Sponsor
The First Affiliated Hospital of Xiamen University
Study ID
NCT06158386
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Chidamide combined with Linperlisib — DRUG
    Specified dose on specified days: Cedarbenzamide (C) 20mg orally twice weekly, Limplica (L) 80mg once daily, 2 weeks on 2 weeks off, Repeat on day 28.

Study Details

To observe the safety and efficacy of Chidamide combined with Linperlisib in the treatment of refractory and relapsed follicular lymphoma.

Key Dates

First listed
Dec 6, 2023
Start date
Nov 22, 2023
Status verified
Feb 2025
Primary completion
Dec 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
33 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Chidamide combined with Linperlisib

Primary Outcome Measure

Complete response rate (CR) [ Time Frame: Up to 24 months ]

Central Contacts

Related Studies